Objectiv e: To evaluate clinical,Quality of Life (QoL) and medical cost outcomes in pati ents with symptomatic reflux esophagitis (RE) receiving different ″triple c ombin ation therapy″ . Methods: A multicent...Objectiv e: To evaluate clinical,Quality of Life (QoL) and medical cost outcomes in pati ents with symptomatic reflux esophagitis (RE) receiving different ″triple c ombin ation therapy″ . Methods: A multicenter medical effectiveness trial conducte d in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were ass ig ned to 8 weeks of ″ triple combination therapy″ with Lansoprazole plus Cisapri de and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes asses sment included symptoms scale scores,RE severity,QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1)M ore Lansoprazole group patients noted RE symptoms resolution than Ranitidine gro up(92.3% vs 78.4%,P<0.01). There was no striking difference between two gro ups in RE healing rate (90.8% vs 82.9%, P>0.05). (2)RE significantly impaire d QoL of patients(P<0.001).Compared with Ranitidine group,QoL in Lansoprazole group had significant improvement (rate of ″good″ QoL 64.5% vs 45.6%,P<0.01). (3)T here w as close correlation between symptomic effectiveness and QoL rating scale in bot h the Lansoprazole and Ranitidine group(P<0.01,r=0.235 and 0.353 respec tively). There were no statistical difference of medical cost between the two groups ( P> 0.05). Conclusion: RE significantly impaired QoL of patients. ″Triple combinati o n therapies″ can significantly improve RE symptoms and QoL. Lansoprazole combin ation therapy was more cost-effective than Ranitidine combination group.展开更多
文摘Objectiv e: To evaluate clinical,Quality of Life (QoL) and medical cost outcomes in pati ents with symptomatic reflux esophagitis (RE) receiving different ″triple c ombin ation therapy″ . Methods: A multicenter medical effectiveness trial conducte d in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were ass ig ned to 8 weeks of ″ triple combination therapy″ with Lansoprazole plus Cisapri de and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes asses sment included symptoms scale scores,RE severity,QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1)M ore Lansoprazole group patients noted RE symptoms resolution than Ranitidine gro up(92.3% vs 78.4%,P<0.01). There was no striking difference between two gro ups in RE healing rate (90.8% vs 82.9%, P>0.05). (2)RE significantly impaire d QoL of patients(P<0.001).Compared with Ranitidine group,QoL in Lansoprazole group had significant improvement (rate of ″good″ QoL 64.5% vs 45.6%,P<0.01). (3)T here w as close correlation between symptomic effectiveness and QoL rating scale in bot h the Lansoprazole and Ranitidine group(P<0.01,r=0.235 and 0.353 respec tively). There were no statistical difference of medical cost between the two groups ( P> 0.05). Conclusion: RE significantly impaired QoL of patients. ″Triple combinati o n therapies″ can significantly improve RE symptoms and QoL. Lansoprazole combin ation therapy was more cost-effective than Ranitidine combination group.
